{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:41:22Z","timestamp":1787496082128,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873786"],"award-info":[{"award-number":["81873786"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.heliyon.2023.e17384","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T12:56:07Z","timestamp":1687265767000},"page":"e17384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of zonisamide as the first additional treatment in Chinese patients with focal or secondary bilateral tonic\u2013clonic seizures: An observational ,prospective study"],"prefix":"10.1016","volume":"9","author":[{"family":"TingtingYang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"CuihuaYan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Huai kuanWu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"JunjiHu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"YujiaoWu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Xue wuLiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2023.e17384_bib1","series-title":"Long-term Safety and Effectiveness of Zonisamide in the Treatment of Epilepsy: a Review of the literature\uff0cNeuropsychiatr Dis Treat 5","first-page":"249","author":"Zaccara","year":"2009"},{"key":"10.1016\/j.heliyon.2023.e17384_bib2","series-title":"Hippocampal CA3 Transcriptome Signature Correlates with Initial Precipitating Injury in Refractory Mesial Temporal Lobe epilepsy\uff0cPLoS One 6","author":"Bando","year":"2011"},{"key":"10.1016\/j.heliyon.2023.e17384_bib3","series-title":"Epilepsy in adults\uff0cLancet 393","first-page":"689","author":"Thijs","year":"2019"},{"key":"10.1016\/j.heliyon.2023.e17384_bib4","series-title":"Epilepsy in China: Major Progress in the Past Two decades\uff0cLancet Neurol 20","first-page":"316","author":"Ding","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e17384_bib5","series-title":"The SANAD II Study of the Effectiveness and Cost-Effectiveness of Levetiracetam, Zonisamide, or Lamotrigine for Newly Diagnosed Focal Epilepsy: an Open-Label, Non-inferiority, Multicentre, Phase 4, Randomised Controlled trial\uff0cLancet 397","first-page":"1363","author":"Marson","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e17384_bib6","series-title":"Managing Drug-Resistant Epilepsy: Challenges and solutions\uff0cNeuropsychiatr Dis Treat 12","first-page":"2605","author":"Dalic","year":"2016"},{"key":"10.1016\/j.heliyon.2023.e17384_bib7","series-title":"Efficacy and Tolerability of Zonisamide versus Controlled-Release Carbamazepine for Newly Diagnosed Partial Epilepsy: a Phase 3, Randomised, Double-Blind, Non-inferiority trial\uff0cLancet Neurol 11","first-page":"579","author":"Baulac","year":"2012"},{"key":"10.1016\/j.heliyon.2023.e17384_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-328X(03)00183-9","article-title":"Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures\uff0cBrain","volume":"116","author":"Ueda","year":"2003","journal-title":"Res Mol Brain Res"},{"key":"10.1016\/j.heliyon.2023.e17384_bib9","series-title":"Clinical Pharmacology and Mechanism of Action of zonisamide\uff0cClin Neuropharmacol 30","first-page":"230","author":"Biton","year":"2007"},{"key":"10.1016\/j.heliyon.2023.e17384_bib10","series-title":"Zonisamide in the Management of Epilepsy in the elderly\uff0cClin Interv Aging 10","first-page":"931","author":"Romigi","year":"2015"},{"key":"10.1016\/j.heliyon.2023.e17384_bib11","doi-asserted-by":"crossref","unstructured":"A. Reimers\uff0cH. Ljung.An Evaluation of Zonisamide, Including its Long-Term Efficacy, for the Treatment of Focal epilepsy\uff0cExpert Opin Pharmacother 20\uff082019\uff09909-15.","DOI":"10.1080\/14656566.2019.1595584"},{"key":"10.1016\/j.heliyon.2023.e17384_bib12","series-title":"Review of Zonisamide Development in Japan\uff0cSeizure 13","author":"Seino","year":"2004"},{"key":"10.1016\/j.heliyon.2023.e17384_bib13","series-title":"Its Pharmacology, Efficacy and Safety in Clinical trials\uff0cActa Neurol Scand Suppl","first-page":"19","author":"Brodie","year":"2012"},{"key":"10.1016\/j.heliyon.2023.e17384_bib14","series-title":"Retention, Dosing, Tolerability and Patient Reported Seizure Outcome of Zonisamide as Only Add-On Treatment under Real-Life Conditions in Adult Patients with Partial Onset Seizures: Results of the Observational Study ZOOM\uff0cSeizure 34","first-page":"66","author":"Hamer","year":"2016"},{"key":"10.1016\/j.heliyon.2023.e17384_bib15","series-title":"Evaluation of Safety and Efficacy of Zonisamide in Adult Patients with Partial, Generalized, and Combined Seizures: an Open Labeled, Noncomparative, Observational Indian study\uff0cTher Clin Risk Manag 12","first-page":"327","author":"Dash","year":"2016"},{"key":"10.1016\/j.heliyon.2023.e17384_bib16","doi-asserted-by":"crossref","unstructured":"E. Trinka\uff0cL. Giorgi\uff0cA. Patten\uff0cJ. Segieth.Safety and Tolerability of Zonisamide in Elderly Patients with epilepsy\uff0cActa Neurol Scand 128\uff082013\uff09422-8.","DOI":"10.1111\/ane.12162"},{"key":"10.1016\/j.heliyon.2023.e17384_bib17","series-title":"Efficacy, Tolerability, and Retention Rates of Zonisamide in Older Adult Patients with Focal-Onset Epilepsy: Experiences from Two Tertiary Epilepsy centers\uff0cEpilepsy Behav 76","first-page":"19","author":"Do\u011fan","year":"2017"},{"key":"10.1016\/j.heliyon.2023.e17384_bib18","series-title":"Zonisamide Add-On Therapy for Focal Epilepsy\uff0cCochrane Database Syst Rev 7","author":"Brigo","year":"2020"},{"key":"10.1016\/j.heliyon.2023.e17384_bib19","series-title":"A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in epilepsy\uff0cDrugs 45","first-page":"760","author":"Peters","year":"1993"},{"key":"10.1016\/j.heliyon.2023.e17384_bib20","series-title":"Carbamazepine Pharmacokinetics Are Not Affected by Zonisamide: in Vitro Mechanistic Study and in Vivo Clinical Study in Epileptic patients\uff0cEpilepsy Res 62","first-page":"1","author":"Ragueneau-Majlessi","year":"2004"},{"key":"10.1016\/j.heliyon.2023.e17384_bib21","series-title":"Lack of Pharmacokinetic Interactions between Steady-State Zonisamide and Valproic Acid in Patients with epilepsy\uff0cClin Pharmacokinet 44","first-page":"517","author":"Ragueneau-Majlessi","year":"2005"},{"key":"10.1016\/j.heliyon.2023.e17384_bib22","series-title":"Lack of Clinically Significant Pharmacokinetic Interactions between Zonisamide and Lamotrigine at Steady State in Patients with epilepsy\uff0cTher Drug Monit 27","first-page":"193","author":"Levy","year":"2005"},{"key":"10.1016\/j.heliyon.2023.e17384_bib23","series-title":"Population Pharmacokinetics of Phenytoin in Japanese Patients with Epilepsy: Analysis with a Dose-dependent Clearance model\uff0cBiol Pharm Bull 19","first-page":"444","author":"Odani","year":"1996"},{"key":"10.1016\/j.heliyon.2023.e17384_bib24","series-title":"Influence of Additional Therapy with Zonisamide (Excegran) on Protein Binding and Metabolism of carbamazepine\uff0cEpilepsia 35","first-page":"1023","author":"Minami","year":"1994"},{"key":"10.1016\/j.heliyon.2023.e17384_bib25","series-title":"The Safety and Long-Term Efficacy of Zonisamide as Adjunctive Therapy for Focal epilepsy\uff0cExpert Rev Neurother 15","first-page":"857","author":"Schulze-Bonhage","year":"2015"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023045929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023045929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:04:32Z","timestamp":1766171072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023045929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2405844023045929"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17384","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of zonisamide as the first additional treatment in Chinese patients with focal or secondary bilateral tonic\u2013clonic seizures: An observational ,prospective study","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e17384"}}